In the IMAD2 (GFPC 01-2018), a retrospective study that included 21 centers in France reported by Guisier et al., 44 ICI-treated BRAF mutant (BRAF V600E, n = 26; BRAF non-V600E, n = 18) NSCLC patients were identified (47). Here, BRAF is linked to non-small cell lung carcinoma.